PURE-XP GliSODin: a catalyst for anti-ageing
20/03/2008
Oxygen is an essential element for life. However, as oxygen and other compounds are broken down by the body, molecules become unbalanced, creating ‘free radicals’ or ‘oxidants’. When free radicals are produced in excess, cells may suffer from oxidative stress which can accelerate signs of ageing such as skin pigmentation and sun damage and lead to a weakened immune system. One of the most harmful of these free radicals is the superoxide molecule.
Fortunately, compounds called antioxidants and in particular Superoxide Dismutase (SOD) have the ability to rapidly quench the superoxide molecule, helping to reduce the harmful effects of free radical damage.
SOD plays an important role in the body’s antioxidant system, intervening by ‘dismuting’ the reactive form of oxygen into ions that are less reactive, thus disabling the superoxide free radicals, the most dangerous cells. This transformation is called dismutation, thus its name dismutase means an enzyme that stops mutation.
SOD not only prevents the multiplication of the superoxide molecule but it is also plays a role in the production of Catalase and Glutathione Peroxidase (Gpx), other antioxidants made by the body to form the internal defence system.
Secondary antioxidants are externally provided from dietary sources such as vitamins (vitamins A, C and E), minerals (selenium, zinc, copper and manganese) and other
substances, including polyphenols which are found in grapes and green tea. Some of the minerals can be utilised by the body to form a part of the SOD molecule. Traditionally free radical damage and oxidative stress have been combated using external antioxidants based on dietary supplementation, to provide additional protection against oxidative aggression.
PURE-XP GliSODin®, new from the Nutri Centre, takes a different approach by priming the body at cellular level to produce its own potent internal antioxidants – including Superoxide Dismutase (SOD), Catalase and Glutathione Peroxidase (Gpx). These provide important levels of defence against oxidative stress and free radical damage, helping to promote the fight against premature ageing. The capacity to combat oxidative stress also helps improve energy levels and vitality and supports the immune system in handling the stresses of everyday life.
Using an organic base of Alfalfa, PURE-XP GliSODin is the first orally effective vegetarian form of Superoxide Dismutase (SOD). Each serving provides a therapeutic dose of 250mg of GliSODin in a bioavailable form protected against gastric degradation.
GliSODin is currently the only Complementary Medical Association (CMA) ‘Approved Product’ in the world. Healthy SOD levels are increasingly identified in scientific research as a key to protecting the body against free radical cell damage. Other health benefits attributed to SOD include reduction in inflammation and inflammatory damage in joints and tissues, protection of the lungs in allergic reactions, protection of the mitochondria (the power house of our cells) from damage, cancer protection and protection for our immune system from environmental toxins.
For a powerful line of defence against oxidative stress, PURE-XP GliSODin. PURE-XP GliSODin costs £24.99 for 30 veg capsules.
To order click on the link below or call 020 7436 5122 to order or speak to a nutritionist for free advice.
Research References
In a double-blind randomized study performed at the University Hospital in Ulm, Germany healthy volunteers are subjected to intense oxidative stress, GliSODin® was shown to protect against cellular DNA damage. Influence of an Orally Effective SOD on Hyperbaric Oxygen-related Cell Damage, C. Muth, Y. Glenz, M. Klaus, P. Radermacher, Guenter Speit, X. Leverve. Free Radical Research, Number 9 (2004) 927–932.
Another double blind human study that showed the use of SOD significantly improved function and reduced pain in patients with active osteoarthritis of the knee. (Lund-Olsen K, Menander-Huber. Intra-articular orgotein therapy in osteoarthritis of the knee. A double-blind, placebo-controlled trial. Arzneimittelforschung 1983; 33(8):1199 -1203.)